Table 1.

Compounds that affect eIF4F assembly or activity

Targets	Compound	Sponsor	Stage of development
mTORC1	Rapamycin (Sirolimus)	Pfizer	FDA approved
	RAD001 (Everolimus)	Novartis	FDA approved
	CCI-779 (Temsirolimus)	Pfizer	FDA approved
	AP23573 (Ridaforolimus)	Merck/ARIAD	Accepted for FDA approval
TOR-KI	Torin1	N/A	Ex vivo cell culture
	INK128	Intellikine	Phase I
	AZD8055	AstraZeneca	Phase I/II
	AZD2014		Phase I
	OSI027	OSI Pharmaceuticals	Phase I
PI3K/TOR-KI	PI-103	N/A	Ex vivo cell culture
	NVPBEZ235	Novartis	Phase I/II
	SF1126	Semafore	Phase I
	GSK2126458	Glaxo Smith Kline	Phase I
	XL765	Exelixis	Phase I/II
	BGT226	Novartis	Phase I/II
	GDC0980	Genetech	Phase I
	PF04691502	Pfizer	Phase I
	PKI587	Pfizer	Phase I
eIF4F	Cap analogs	N/A	In vitro studies
	4Ei-1	N/A	In vitro studies
	4EGI-1	N/A	Ex vivo cell culture
	4E1RCat	N/A	Active in preclinical models
	4E2RCat	N/A	Active in preclinical models
	ISIS-EIF4ERx	Eli Lilly/ISIS	Phase II
	Pateamine A	N/A	Ex vivo cell culture
	DMDA-Pat A	N/A	Active in preclinical models
	Hippuristanol	N/A	Active in preclinical models
	Rocaglamides (Silvestrol)	N/A	Active in preclinical models
Mnk	Cercosporamide	Eli Lilly	Active in preclinical models
	CGP57380	Novartis	Ex vivo cell culture